Moreover, recent study indicated that Brother of The Regulator of Imprinted Sites (BORIS, also known as CTCFL), a paralog of CTCF, is aberrantly upregulated in prostate, ovarian, lung and breast cancers (90–93) and its expression is correlated with tumour characteristics and therapeutic response (94). This evidence concerns the gene CTCFL and breast cancer.